G protein–coupled receptors (GPCRs) are a large and ubiquitous class of membrane receptors that are important targets for drug discovery. Until now, most assays of GPCR function have been performed in ...

In this webinar, Robert Lowrey and David Siderovski will discuss novel AI-driven drug discovery approaches targeting ...

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. With rapid ...

Structure Therapeutics (GPCR) is stepping into the spotlight as it prepares to release topline data from its ACCESS trial of aleniglipron, an oral GLP 1 candidate for obesity, along with a same day ...

Shares of Structure Therapeutics GPCR skyrocketed 102.5% after the company reported positive top-line data from the ACCESS clinical program of aleniglipron for the treatment of obesity and/or ...

Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

1 Day GPCR -1.94% DJIA -0.04% S&P 500 -0.03% Health Care/Life Sciences -0.01% ...